TRACON Pharmaceuticals, Inc. (TCON)
| Market Cap | 109.72K |
| Revenue (ttm) | 3.20M |
| Net Income (ttm) | 5.20M |
| Shares Out | 3.41M |
| EPS (ttm) | 2.27 |
| PE Ratio | 0.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 11,532 |
| Open | 0.0322 |
| Previous Close | 0.0322 |
| Day's Range | 0.0322 - 0.0322 |
| 52-Week Range | 0.0210 - 14.7400 |
| Beta | 1.36 |
| RSI | 43.38 |
| Earnings Date | Nov 8, 2024 |
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also in... [Read more]
Financial Performance
Financial StatementsNews
Himax Technologies: Navigating The Down Cycle
Himax's automotive business, including DDIC, TDDI, TCON, LTDI, and OLED, showed significant growth, accounting for over 47% of total sales. See why I rate HIMX buy.
TRACON Pharmaceuticals Announces it Will Wind Down Operations
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was mad...
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiot...
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Charles Theuer - President & CEO Scott Brown - CFO Conference Call Participant...
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development plat...
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development plat...
TRACON Pharmaceuticals Announces Reverse Stock Split
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform...
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
Objective Response Rate by investigator review increased to 15% since interim analysis in September Full ENVASARC enrollment expected in 1Q 2024 and final data anticipated during 3Q 2024 SAN DIEGO, De...
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Dr. Charles Theuer - President and CEO Scott Brown - CFO Conference Call Pa...
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 Full ENVASARC accrual expected in Q4 and final data expected in mid-2024
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pl...
TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q2 2023 Earnings Call August 14, 2023 4:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B.
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...
TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development pla...
TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...
TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call P...
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development plat...